Why Paraguay and Argentina Have Tirzepatide While Brazil Waits

The FDA approved Mounjaro (tirzepatide) in May 2022 for treating type 2 diabetes, and the European Medicines Agency followed later that same year. Yet in Brazil, this dual GLP-1 and GIP receptor agonist remains unregistered. So why do Paraguay and Argentina have tirzepatide products while Brazil waits? The answer involves regulatory systems, patent enforcement, and decisions made by pharmaceutical companies that directly shape what medications patients can access.

The GLP-1 Market in South America Today

When Eli Lilly received FDA approval for Mounjaro, it marked a significant advancement in diabetes and obesity treatment. The medication works by activating both GLP-1 and GIP receptors, which may help regulate blood sugar and appetite. European regulators approved it later that year, opening access across the EU.

Demand for effective weight management medications has grown substantially across South America, creating a wide gap between what patients need and what they can legally access locally. Patients in Brazil, Paraguay, and Argentina each face completely different realities when trying to obtain tirzepatide. This regional disparity raises important questions about how regulatory processes, intellectual property enforcement, and local pharmaceutical manufacturing capacity shape medication availability.

How Paraguay's Regulatory Framework Differs from Brazil's

Paraguay's health authority, DINAVISA, operates under pharmaceutical registration requirements that differ substantially from Brazil's ANVISA. Paraguay's smaller pharmaceutical market and different approach to intellectual property enforcement have historically allowed earlier production or import of drugs that remain under patent protection elsewhere. The country has become known as a source for medications that are either unregistered or sold at lower prices compared to neighboring nations.

DINAVISA's registration process for new molecules does not always mirror the patent status enforced internationally. This means manufacturers or distributors may register products in Paraguay that would face legal barriers in countries with stricter IP enforcement. For patients in Brazil, this regulatory difference creates an informal pathway to access medications unavailable at home, though with inherent risks regarding product quality and authenticity.

Argentina's Approach to GLP-1 Medications and Local Production

Argentina's ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) maintains its own evaluation pathway for drug approvals, separate from both Brazil and the United States. Argentina has a long tradition of local pharmaceutical manufacturing, including experience with complex biologic and biologic-like products. Economic pressures and currency restrictions over the years have encouraged domestic production of medications that would otherwise require expensive imports.

Whether Argentina produces a direct generic or a similar product depends on how regulators classify the medication and whether patent protections are actively enforced locally. This flexible approach has allowed Argentine patients greater access to certain medications compared to their Brazilian neighbors.

Why Brazil's ANVISA Has Not Registered Tirzepatide

ANVISA requires comprehensive clinical data, manufacturing inspections, and patent clarity before granting registration for any new drug. These requirements ensure safety and efficacy but also extend the approval timeline significantly. Brazil's patent system and ANVISA's reliance on patent status mean that even if an application were filed, market exclusivity could delay public availability.

The combination of strict regulatory requirements and manufacturer decisions creates a bottleneck that does not exist in Paraguay or Argentina. Unlike those countries, Brazil has not seen a tirzepatide product receive local approval through any pathway.

The Compounded Medications Question in Brazil

Brazil's CFM restrictions on compounded GLP-1 medications affect tirzepatide differently than semaglutide because tirzepatide is not even registered in the country. Pharmacies cannot legally compound a drug that has no reference product registered in Brazil. This creates a legal gap that prevents patients from accessing tirzepatide through traditional pharmacy channels.

Patients seeking tirzepatide in Brazil often look to Paraguay or import it personally, creating legal and safety gray areas. This situation differs from semaglutide, which has Ozempic registered in Brazil, even if compounding is restricted. The Ozempic registration at least gives Brazilian patients a legal pathway to access a GLP-1 medication, however different the drug may be.

What This Means for Patients in Each Country

Patients in Paraguay may access tirzepatide more easily but face questions about product quality, storage conditions, and counterfeit risk. Patients in Argentina may have local access but the product's origin and regulatory status can be unclear. Brazilian patients are left without legal access to tirzepatide specifically, relying on alternatives like Ozempic or looking abroad.

The disparity highlights how regulatory decisions in one country directly shape what medications patients can legitimately access in neighboring countries. What works in one regulatory framework may simply not be available next door.

What Could Change and What Patients Should Watch

Eli Lilly could decide to file for ANVISA registration, which would start a process that typically takes years but would eventually open legal access. Patent expirations in the future could open the door for generic registrations in Brazil, similar to what happened with other biologic drugs. Regulatory harmonization efforts in South America could eventually reduce these access gaps, though progress is slow.

Until then, patients should stay informed about the legal status of any medication they consider and consult healthcare providers familiar with both Brazilian regulations and international options. For now, Ozempic remains the registered GLP-1 option available within Brazil's regulatory system.

FAQ

Has ANVISA approved tirzepatide in Brazil?

No. As of now, ANVISA has not registered tirzepatide (sold as Mounjaro in other countries) for sale in Brazil.

Why do Paraguay and Argentina have tirzepatide products while Brazil does not?

Each country has its own regulatory authority and timeline for drug approval. Paraguay's DINAVISA and Argentina's ANMAT operate under different requirements than Brazil's ANVISA, and local manufacturing capacity in Argentina has allowed access to certain medications that remain unregistered in Brazil.

Can Brazilian patients legally obtain tirzepatide?

Brazilians cannot legally purchase tirzepatide within Brazil since it is not registered with ANVISA. Some patients travel to neighboring countries or use personal importation channels, though these options carry legal and safety considerations.

What GLP-1 medication is available in Brazil?

Ozempic (semaglutide), manufactured by Novo Nordisk, is registered with ANVISA and available by prescription in Brazil. It works differently from tirzepatide but offers a legal pathway to access GLP-1 therapy domestically.

What should patients consider before seeking tirzepatide abroad?

Patients should verify that any medication obtained internationally has been properly stored and handled, as improper conditions can compromise drug effectiveness. Consulting a healthcare provider familiar with Brazilian regulations and international medication options can help patients make informed decisions.

Sources

• FDA Approves Novel Drug for Type 2 Diabetes
• EMA Mounjaro Product Information
• ANVISA Drug Registration Requirements